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Summary. Introduction: The treatment of cystic fibrosis (CF) is directed toward correction of organ
dysfunction and relief of symptoms resulting from the disease. Lack of adherence to daily treatment
regimens may have substantial short-term and long-term effects on patients with CF. In this study,
we attempted to identify barriers to treatment adherence which could be predicted by objective
measures and explore ways to improve adherence in adolescents with CF. Methods: A
questionnaire was given to patients 12.0–20.9 years of age, designed with focus on specific
barriers to adhering to treatment plan and related attitudinal patterns. Observational and analytical
results were collected. Results: We obtained questionnaires and objective health data for
60 respondents. The most commonly identified barriers to adherence were forgetting or losing
medications (32/60) and being too busy (23/60). Attitudinal patterns that played a significant role for
nonadherence included unintentional forgetting (40/60), feeling that following CF treatments
resulted in less freedom in their lives (30/60), and believing it is acceptable to miss a treatment every
fewdays (18/60)or to miss treatmentswhen busy (18/60). Discussion: There were a few statistically
significant differences of adherence patterns between demographic subgroups in our study. Males
were more likely to agree that it is acceptable to miss doses if theyare made up with extra doses later
(24% vs. 3%, P¼ 0.04). Patients who perceived themselves to be less healthy agreed more to
statements of limited freedom, nonsympathetic medical providers, and difficulty adhering
during times of decreased symptoms. This highlights an unexpected risk: as CF progresses and
patients perceive themselves to be less healthy, they may become less likely to be adherent during
theperiods theyare feeling thebest, whileat the same time becoming less likely to perceive empathy
from their physicians. Conclusions: Survey results describe a variety of beliefs and attitudinal
patterns which contribute to nonadherence in CF treatment, especially relating to time manage-
ment. While patients largely understood the importance of treatments to their health, predictors of
risky behaviors could lead to targeted interventions by CF centers to address these challenges and
improve adherence. Pediatr Pulmonol. 2010; 45:450–458.  2010 Wiley-Liss, Inc.
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INTRODUCTION
The management of cystic fibrosis (CF) in patients of all
ages is directed toward treatment of organ dysfunction and
relieving symptoms resulting from the disease. Earlier
diagnosis by newborn screening, advances in the treat-
ment of the disease, and improved quality of care have all
led to a steady increase in median predicted survival age,
now standing at 37.4 years by 2007 data.1,2 Pulmonary
disease, however, remains the most common cause of
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morbidity and mortality, with patients suffering recurrent
exacerbations and progressive deterioration of their lung
function.3,4 Daily CF treatment typically includes inhaled
and oral respiratory medication, physiotherapy, exercise,
and oral pancreatic enzyme and multivitamin supplements
for treatment of pancreatic insufficiency and fat malab-
sorption.5 The number of medications and therapies
required to treat CF increases as disease severity
progresses.6,7 The lack of adherence to daily treatment
regimens has been demonstrated to have substantial
impact on the health of patients with CF.8,9
Due to the increasingly observed connection to
morbidity and mortality, adherence to treatment recom-
mendations has been an increasing focus for physicians
and other CF healthcare providers.10–13 Poor adherence
to medication regimens in patients with life-threatening
chronic disease is a common problem, and for decades
there have been published studies reviewing and
summarizing this issue.10 The mean adherence rate for
long-term preventative regimens has been calculated
to be 57%, with a range of 33–94%, and for long-
term treatment regimens the mean was 54%, with a
range of 41–61%, with more recent work supporting
these findings for CF.11 One contributor to nonadherence
is that physician treatment recommendations may be
poorly understood by parents, children, or adoles-
cents.10,14 In addition, parents, children, and physicians
all may have different understandings of severity of
illness and necessity of certain treatments, which is likely
to intensify adherence problems.12,13
Research on adherence to the medical regimen in CF
patients has often relied on subjective measures, including
the use of interviews and/or questionnaires,10–12 with
some recent studies focusing more on objective measures.
An assessment of the rates of adherence in children with
CF aged 6–13 years using four different measurement
methods was recently performed.15 Adherence measures
included parent and child self-reports, diary data,
pharmacy refill history, and electronic monitors. Results
suggested that rates of adherence varied by treatment
component and across measurement methods. However,
when examining more objective measures, rates of
overall adherence were below 50% for children with CF,
indicating generally poor adherence to treatment
regimen. We previously studied adherence objectively in
44 patients with CF.16 Children less than 12 years of age
(Group 1) and adolescents 12 years of age and older
(Group 2) were recruited. Adherence to ADEKs, an oral
multivitamin, was monitored using the Medication Event
Monitoring System (MEMS) Smart Caps (APREX,
AARDx, Inc., Union City, CA). Dornase alfa, a nebulized
mucolytic medication, was monitored by counting empty
vials. The overall mean adherence rates for ADEKs and
dornase alfa were (SD) 63.6 24.0% and 66.5 31.2%,
respectively. The median ADEKs and dornase alfa
adherence rate for Group 1 was 84.6% and 79.1%,
respectively (P¼ 0.08); and for Group 2 was 56.7% and
85.4%, respectively (P¼ 0.07). Due to these differences in
adherence between the age groups in regard to each
medication, we concluded that parental supervision and
disease severity are likely to play a major role in adherence
to medical management. Partnership with patients and
families about the treatment plan could be important for
improving adherence rates.16
Barriers to treatment adherence for children aged 6–
13 years with CF and asthma were also studied.17 Results
indicated that barriers were quite similar by illness and by
informant (e.g., parent or child) for the same treatments,
but unique barriers were identified for disease-specific
treatments. Frequently mentioned barriers across diseases
included forgetting, oppositional behaviors, and difficul-
ties with time management. Trends were identified
between adherence and barriers, suggesting that having
a greater number of barriers was related to poorer
adherence.17
In this study, we are interested in identifying barriers to
treatment adherence and attitudinal patterns in adoles-
cents with CF, and thus exploring ways to improve
adherence. As seen from our previous study, adolescents
are likely to have different adherence rates than younger
children to various medications.16 As that study showed
adherence rate differences across age categories, we
hypothesize that the barriers to adherence could also vary
by age. We have therefore tried to evaluate if adolescents
present with unique barriers to adherence compared
with other patients with CF. We also hypothesize that
within adolescent and young adult patients, objective
characteristics (sex, age, disease severity) could predict
which barriers are most likely playing a role in individual
nonadherence. Since health perceptions have been
found to play a role in adherence for adolescents,13 we
additionally studied subjective self-categorization of
health against barriers to adherence.
MATERIALS AND METHODS
Participants
Study participants included 60 adolescents and young
adults recruited from the University of Michigan Cystic
Fibrosis Center. Eligibility criteria included: (a) age
between 12.0 and 20.9 years, and (b) CF diagnosed by
sweat chloride 60 meq/L or two disease-causing muta-
tions. The patient population meeting these criteria
included 101 patients. Given the age range and the time
frame of data collection (2007–2008), participants
included both individuals born in the late 1980s and those
born in the early to mid-1990s, when expectations of care
and longevity were notably different. The study was
approved by an Institutional Review Board at the
University of Michigan.
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Questionnaire
A questionnaire was designed by a post-graduate fellow
in the Institute for Social Research at the University of
Michigan. It was created to identify barriers for adoles-
cents with CF in adhering to their treatment plans. There
were four main sections to the questionnaire, and a total of
98 questions (including subquestions) were present. The
first section addressed the patient’s self-perception
regarding physical health, disease severity, and level of
daily functioning. The second section included multiple
questions for several specific CF therapies to clearly
identify which treatments an individual respondent was
presently using. The third section listed 10 different
attitudinal patterns of nonadherence; the respondent
would select from a 5-point Likert scale of ‘‘Strongly
agree’’ to ‘‘Strongly disagree’’ for each assertion. The
final section allowed the participant to identify answers
from lists of most prominent barriers, specific treatments
likely to be missed, and family members influential to
adherence. There was space for written feedback at the end
of the questionnaire to elaborate further on the answers
provided.
No scoring system or summary equations were used to
interpret the data; individual questions were analyzed
separately. The questionnaire developed for this study
adapted several questions which have demonstrated
reliability and validity in previous studies, including the
Disease Management Interview-CF (DMI-CF),12,17 the
Barriers to Adherence Interview-CF,17 the National
Health Interview Survey (NHIS)18 and the Adherence
Attitude Inventory (AAI).19 As each section was assessing
different constructs, no factor analysis was performed
specifically for our questionnaire. Instrument reliability
and internal consistency were demonstrated through
statistical agreement between subjective and objective
health measures (see the Results Section), and psycho-
metric properties of the source inventories are reasoned to
be maintained in our questionnaire.
Procedure
Patients were asked to complete the questionnaire
either during a routine clinic visit, hospitalization, or via
mail. After obtaining informed consent, the patients were
allowed time to complete the questionnaire. Participants
were reassured that their responses would be confidential
and not shared with the healthcare team. If a patient could
not complete the questionnaire during the clinic visit, they
were permitted to take it home and mail it back when
finished. The questionnaire was completed only once
per patient. Four of these 60 responses could not be used in
the analysis due to inadequate obtainment of consent or
assent, or due to incomplete questionnaires.
Thirty patients who were not recruited during clinic
visits or hospitalization were mailed the consent, assent,
questionnaire, and a letter explaining the study. Four of
these patients mailed back the completed consent, assent,
and questionnaire.
Other Measures
Patient age, sex, weight, height, body mass index
(BMI), BMI percentile, and pulmonary function testing
results were captured for all respondents to evaluate
demographics and disease severity. These data were
obtained from the clinic visit or hospitalization closest
to the date that the patient completed the questionnaire.
The same data were also collected for the 41 patients who
did not participate in the study. The data for participating
and nonparticipating patients were compared to assure
that there were no significant differences between the two
groups.
Analysis Methods
For the patients who did participate, the results of the
questionnaire were combined with objective measures of
disease severity. Subgroup analysis was performed based
on sex, age categories, and health—both objective
measures and self-perception. Initial data analysis,
including the primary summary and analysis of survey
responses, was performed using descriptive statistics.
Confidence intervals for specific survey responses were
calculated using the normal approximation method.
Responses to questions employing a Likert-type scale
of possible answers were evaluated as both categorical
and continuous responses (i.e., 1–5 vs. Poor–Excellent).
Comparisons of survey responses between specific
subgroups of interest were performed using the chi-
squared distribution or Fisher’s exact test for categorical
variables and Student’s t-test for continuous variables. All
statistical tests were performed using SAS for Windows
9.2 (Cary, NC). All summary data are presented as mean
(standard deviation), median (range), or number (%) as




Study participants included 60 patients. Descriptive
information for the study population and the male/female
subgroups are summarized in Table 1. The mean age of
participants was 16.3 years and 58% were females.
Descriptive data for survey participants and the non-
participants (41 patients) were compared. Statistical tests
revealed no significant differences in sex distribution, age,
BMI, FEV1%, FEF25–75%, and genotype results between
respondents and nonrespondents (Table 1).
No significant difference was found between the male
and female participant subgroups for average age, BMI,
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FEV1%, and FEF25–75%. In addition, there were no
statistically significant differences in the number of CF
respiratory therapies between males and females.
Subgroups were created to compare younger (12.0–
15.9 years, n¼ 27) and older (16.0–20.9 years, n¼ 33)
participants. There was a similar sex distribution in the age
categories (younger group is 63% female; older group is
55% female, P¼ 0.511).
As would be expected, there were notable differences in
health status based on age category. While the younger
patients had an average FEV1% of 92 with 67% of them
self-reporting better health (see next paragraph), the older
patients’ average FEV1% was 71 (P 0.001) with only
45% reporting to have better health (P¼ 0.100).
Self-reported health was based on a survey question:
‘‘In general, would you say your health is excellent, very
good, good, fair, or poor?’’ Those who were considered
to be self-reporting comparatively better health answered
‘‘excellent’’ or ‘‘very good’’ (n¼ 33). These patients
tended to be younger and objectively more healthy (i.e.,
greater FEV1%) than patients who rated their health as
only ‘‘good,’’ ‘‘fair,’’ or ‘‘poor’’ (Table 2).
Objective health categories were compared using a
cutoff of FEV1% of 70. Those above this threshold
(n¼ 43) also had significantly lower age (15.8 years vs.
17.6 years, P¼ 0.001) and higher BMI (21.6 vs. 19.2,
P¼ 0.008) than patients at or below FEV1% of 70
(Table 2). These results were comparable to the subjective
self-perception of health reported by the patients.
Specific Treatments
Participants self-reported their respiratory treatments.
In addition, they were asked which treatments were
acceptable to occasionally miss, with no limit to the
number of treatments that could be chosen (Fig. 1).
Results are reported only for actual current users of the
treatment type, thus creating a different denominator for
each treatment. Airway clearance techniques were the
most likely to be listed as acceptable to occasionally miss
Pediatric Pulmonology
TABLE 1— Descriptive Information of Respondents Versus Nonrespondents, and Male Versus Female Respondents1
Respondents Male Female P-value Nonrespondents P-value
N 60 25 35 41
Age (years) 16.3 2.1 16.4 1.8 16.2 2.2 0.688 16.7 2.3 0.361
Age <16 years 27 (45.0%) 10 (40.0%) 17 (48.6%) 0.602 18 (43.9%) 0.973
BMI 20.9 3.5 20.4 3.3 21.3 3.6 0.297 20.3 3.0 0.323
BMI% 47.8 32.0 40.8 33.6 52.8 30.2 0.160 41.5 28.3 0.304
FEV1% 80.6 24.5 79.9 25.9 81.2 23.9 0.845 78.4 25.9 0.663
FEF25–75% 69.4 36.9 63.8 35.5 73.4 37.8 0.323 50.7 35.4 0.307
Known genetic mutations 41 (68.3%) 17 (68.0%) 24 (68.6%) 1.000 32 (78.0%) 0.538
DF508 homozygous2 20 (48.8%) 7 (41.2%) 13 (54.2%) 0.3963 16 (50.0%) 0.7183
DF508 heterozygous2 13 (31.7%) 5 (29.4%) 8 (33.3%) — 11 (34.4%) —
Other mutations2 8 (19.5%) 5 (29.4%) 3 (12.5%) — 5 (15.6%) —
1All data presented as mean standard deviation or as number (%), as appropriate.
2Percentage of those with known mutation status.
3Comparison of DF508 genotypes.




less healthy P-value Higher FEV1% Lower FEV1% P-value
N 33 27 43 17
Age (years) 15.5 1.9 17.2 1.9 0.002 15.8 2.0 17.6 1.7 0.001
Age <16 years 18 (54.5%) 9 (33.3%) 0.123 24 (55.8%) 3 (17.7%) 0.010
BMI 20.9 3.3 21.0 3.8 0.927 21.6 3.5 19.2 2.9 0.008
BMI% 51.9 31.8 42.7 32.1 0.273 57.3 28.0 23.8 29.3 <0.001
FEV1% 89.7 21.4 69.6 23.9 0.001 93.9 12.2 47.1 12.3 <0.001
FEF25–75% 84.8 34.0 50.6 31.6 <0.001 88.7 23.2 20.6 8.4 <0.001
Known genetic mutations 26 (78.8%) 15 (55.6%) 0.093 32 (74.4%) 9 (52.9%) 0.131
DF508 homozygous2 13 (50.0%) 7 (46.7%) 0.1863 17 (53.1%) 3 (33.3%) 0.4273
DF508 heterozygous2 10 (38.5%) 3 (20.0%) — 10 (31.3%) 3 (33.3%) —
Other genotype2 3 (11.5%) 5 (33.3%) — 5 (15.6%) 3 (33.3%) —
1All data presented as mean standard deviation or as number (%), as appropriate.
2Percentage of those with known mutation status.
3Comparison of DF508 genotypes.
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(52% of users), while other treatments were listed by 14–
36% of their users. The exception was inhaled tobramycin,
which was not listed by any of the 23 users as acceptable to
miss. Questionnaire results also demonstrated that 32/60
respondents (53%) were current users of inhaled cortico-
steroids; however, information could not be accurately
gathered about nonadherence acceptability for this treat-
ment due to details of survey design.
Specific Barriers
A list of 14 barriers to treatment adherence was
presented to participants. They were asked to choose two
answers that represented their greatest personal barriers.
While a single patient chose more than two answers
(which were excluded from analysis) and a minority of
participants chose no answers or only one answer, the
majority chose two responses, resulting in 100 total
answers (Fig. 2). By far, the most selected responses were
issues of time management: forgetting treatments, being
too busy, and having too many treatments to manage.
When responses were compared between subgroups (by
sex, age, subjective health, or FEV1% values), no
significant differences were seen. There was some non-
significant age stratification; for instance, while the older
subgroup (which also had less optimal health) was more
likely to identify busyness as a barrier to adherence (45%
vs. 26%), the younger subgroup was more likely to
identify a desire to be normal as a barrier (19% vs. 6%).
Attitudinal Patterns
Our questionnaire included 10 statements of attitudinal
patterns, each of which could be associated with poor
adherence, and asked participants to rate their agreement
with the statements on a 5-point Likert scale (Table 3). The
statements covered a variety of attitudes about CF
treatments, but all can be generally considered to be less
desirable attitudes than their converse statements. Anal-
ysis centered on total numbers of respondents who
expressed agreement with the statement (choosing
‘‘Strongly Agree’’ or ‘‘Somewhat Agree’’), as well as
comparison of agreement levels between subgroups.
Most statements had a low percentage of total
respondents who expressed agreement. Only three state-
ments received higher than 30% agreement: ‘‘Even
though I want to follow my treatments, sometimes I just
forget’’ (67%); ‘‘Having to follow the treatments for cystic
fibrosis means I have less freedom in my life’’ (50%); and
‘‘I have trouble sticking to my treatments when I have no
physical symptoms’’ (42%). Comparing the younger
patients (age 12.0–15.9 years) to the older patients (age
16.0–20.9 years), there were no significant differences in
agreement level for any of these questions using this
binomial approach. In comparing males and females, only
one statement showed a significant difference in agree-
ment: ‘‘It is OK to miss a treatment as long as I make up for
it with an extra dose the next time’’ had agreement from
24% of males and only 3% of females (P¼ 0.017).
Comparison of attitudinal patterns was made between
subgroups based on health status, using two separate
measures. First, our objective measure showed no
significant difference in agreement to any of the state-
ments between those with FEV1% greater than 70 versus
those with lower values. However, the subjectively
healthier group had significant differences on level of
agreement with three of the statements compared to the
self-described less healthy group: ‘‘My primary team does
not fully understand how difficult it is for me to follow the
treatments when I am supposed to’’ (6% vs. 33%;
P¼ 0.009); ‘‘Having to follow the treatments for cystic
fibrosis means I have less freedom in my life’’ (30% vs.
74%; P¼ 0.002); and ‘‘I have trouble sticking to my
treatments when I have no physical symptoms’’ (24% vs.
Pediatric Pulmonology
Fig. 1. Perceived acceptability of missing specific treatments
(as a percent of respondents who are currently using each
therapy; numbers on the columns represent actual number of
patients).
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63%; P¼ 0.004). In each of these statements, the group
which self-describes as less healthy was significantly
more likely to agree with the statement.
DISCUSSION
As nonadherence can profoundly affect long-term treat-
ment plans and outcomes of patients with CF, this study
was designed to identify specific barriers to adherence
which adolescent patients are facing. Since this is
questionnaire-based research, we have primarily collected
subjective data of the patients’ perceived experiences and
challenges. This has been combined with objective patient
measures and analyzed for relevant information.
Importantly, we found that the respondents generally
recognized the value of adhering to their treatment plans.
The treatment most likely to be perceived as acceptable to
miss, airway clearance therapy (with a large majority
using a vest), is time-consuming and can be uncomfort-
able. In addition, because it is not pharmacologic, there
may be a perception that it is less essential to maintaining
health. This correlates well with a recent study in Spain
which observed less adherence for airway clearance than
for other respiratory treatments, with more patients
claiming the chest therapy did not improve their quality
of life.20 In our results, the one therapy which no
respondents answered to be acceptable to miss, inhaled
tobramycin, might be perceived as especially important
because of its antibiotic activity. As it is typically
prescribed in cycles (28 days on treatment followed by
28 days off), we would also speculate that having a specific
short-term end date to treatment course may improve
adherence by making the regimen feel more tolerable and
finite. Additionally, patients may feel improvement in
their symptoms while on treatment cycle, which could
enhance adherence.
Respondents predominantly reported issues of time
management to be the specific barriers that inhibited
adherence; these findings are also reflected in other
research with a younger patient population.17 This would
suggest that interventions to improve adherence may be
best targeted at this concern. Some of these interventions
may include technologic advances: for example, therapies
may be developed which can be completed in less time and
in combination with each other. Beyond this, however,
there may be more basic approaches in time management
counseling not unlike what would be ascribed for any
person managing a complex daily schedule of tasks. Some
of these barriers and their potential interventions may be
age-specific as well. For instance, younger adolescents
reported more concern about embarrassment and wanting
to be normal and they may need more targeted guidance
about the benefits and possible drawbacks of disclosure to
peers. At the same time, it is important to consider that
while respondents offered these specific issues as their
greatest barriers to adherence, these may only be the most
Pediatric Pulmonology
Fig. 2. Self-reported barriers to adherence. None of the respondents chose the following barriers:
difficult to understand physician’s instructions; no longer a need for medication; family
emergencies; technique problems; financial problems.
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superficial barriers to acknowledge. Other obstacles to
treatment adherence may lie deeper in the psychosocial
framework, to the awareness of the patient or not.
Presenting respondents with specific attitudinal patterns
allowed us to identify thought processes and belief patterns
which may be underlying their nonadherence. Relatively
high levels of agreement that CF treatments lead to less
freedom and that forgetfulness can affect treatment
adherence were not surprising to us and concur with
previous study.6 Although other research has shown
differences in adherence rates and in emotional impact
of CF between male and female adolescents,21 our study
demonstrated almost no distinction in attitudinal patterns
between the sexes. However, the most telling data from
this set of answers may be the differences between the self-
perceived healthier and less healthy subgroups. Other
work has suggested that deterioration of physical health in
CF may be associated with impaired overall psychological
and psychosocial functioning.22,23 In our study, as patients
perceived themselves to be less healthy, they were
significantly more likely to agree that their healthcare
providers did not understand adherence challenges, free-
dom was being restricted, and adherence was more
challenging during times when they felt relatively better.
This can provide some insight into a cycle of worsening
symptoms. As the patients’ baseline health diminishes and
number of routine treatments increases, they can experi-
ence treatment fatigue and brief windows of improved
symptoms may inspire self-prescribed ‘‘treatment holi-
days.’’ Other recent research has demonstrated that
physicians are more likely to discuss the importance of
adherence with patients when they are experiencing
worsening symptoms.24 Our findings suggest that it may
actually be their periods of best health when patients are
Pediatric Pulmonology
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most tempted to skip their scheduled treatments, and that
may be when anticipatory guidance about adherence and
time management could be most valuable. It is also notable
that the significant differences in attitudinal pattern
responses were seen when comparing self-perceived
health and not seen when comparing FEV1% values; our
interventions into nonadherence may need to take into
account the patients’ own health perceptions and not just
their objective data to most accurately identify their
concerns.
The goal of this study was to learn about treatment
adherence among patients with CF by characterizing
adherence determinants in our local CF population. To
that end, the statistical analysis included primarily
descriptive statistics, with some additional two-group
comparisons (subgroup analyses) being made using
straightforward statistical tests. No sample size calcula-
tions were performed since the study attempted to include
the entire local population and then to make reasonable
inferences regarding the broader CF population by
comparing the local population to other populations of
patients with CF. However, to provide some reference for
how well the main responses regarding adherence
attitudes reflect those of the broader CF population, 95%
confidence intervals were calculated (Table 3).
Objective data from the nonrespondents suggest that the
participants in this study are representative of the wider
adolescent and young adult population in our CF center.
However, we cannot exclude the possibility that those
patients who opted not to complete a questionnaire would
have different perceptions and adherence behaviors than
respondents. Choice of study participation, as in nearly all
clinical or behavioral research, may create a nonrepre-
sentative sample. The different era of CF care that our
younger patients were born into, in comparison to the
older subset, could also confound any age-related differ-
ences that were observed in the study. Treatment options
and expectations for survival were markedly more limited
in the 1980s and this may have effects on the older
patients’ attitudes and disease progression that were not
captured in our data. There were other limitations inherent
to our study design as well: our objective health data
(FEV1%, BMI, etc.) was not always collected on the
same day as completion of the questionnaire if it was
submitted via mail, and variability may have been
introduced by the multiple settings in which question-
naires were completed.
There is growing literature that demonstrates the
enormous impact of nonadherence on health outcomes
for patients with CF. Our study was unique in how it was
designed to incorporate the perceptions of adolescent
patients into our understanding of specific barriers. Both
internal barriers (attitudinal patterns) and external barriers
(such as social and economic factors) were examined.
Certain behaviors, especially relating to time manage-
ment, are clearly identified by adolescents as barriers to
adherence. Their attitudes and perceptions about CF can
also affect adherence, and these patterns have potential to
be predicted by sex, age, and disease progression.
Interventions could be targeted to individual nonadherence
risk factors once these aspects are better understood. We
believe that programs that address these challenges would
improve adherence and could be further studied for
effectiveness.
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